Apple
AAPL
Cisco
CSCO
Disney
DIS
4
Qualcomm
QCOM
5
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
CGTX Cognition Therapeutics
- 0.421
- +0.005+1.23%
Close Mar 31 16:00 ET
- 0.432
- +0.011+2.66%
Pre 08:28 ET
26.08MMarket Cap-0.49P/E (TTM)
0.434High0.390Low456.66KVolume0.420Open0.416Pre Close187.94KTurnover0.82%Turnover RatioLossP/E (Static)61.97MShares2.95052wk High1.39P/B23.41MFloat Cap0.34052wk Low--Dividend TTM55.63MShs Float13.800Historical High--Div YieldTTM10.54%Amplitude0.340Historical Low0.411Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Cognition Therapeutics Stock Forum
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes
Tuesday, 1st April at 7:30 am
PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in m...
Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial
Benzinga· 1 min ago
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease at the AD/PD 2025 Alzheimer's & Parkinson's Diseases Conference ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
5 MINUTES AGO, 4:05 PM EDT
VIA GLOBENEWSWIRE
PURCHASE, N.Y., March 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), announced that President and CEO Lisa Ricciardi will present live at the Life Sciences Virtual Investor Conference on March 13, 2025 at 9:30 a.m. ET. In her ...
No comment yet